CEL-SCI Corporation (CVM)
NYSEAMERICAN: CVM · Real-Time Price · USD
1.520
+0.160 (11.76%)
At close: Aug 5, 2026, 4:00 PM EDT
1.510
-0.010 (-0.66%)
After-hours: Aug 5, 2026, 6:51 PM EDT
CEL-SCI Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
44
Market Cap
26.57M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | - | - | - |
| Sep 30, 2024 | - | - | - |
| Sep 30, 2023 | - | - | - |
| Sep 30, 2022 | - | - | - |
| Sep 30, 2021 | - | - | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Barinthus Biotherapeutics | 14.97M |
| Evaxion | 7.53M |
| Longeveron | 1.22M |
| IGC Pharma | 1.11M |
| ABVC BioPharma | 797.92K |
| Allarity Therapeutics | 345.00K |
| Actinium Pharmaceuticals | 90.00K |
| Neuphoria Therapeutics | -13.27K |
CVM News
- 1 day ago - CEL-SCI announces publication of study supporting multikine biomarker strategy - TheFly
- 1 day ago - CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study - Business Wire
- 6 days ago - CEL-SCI announces manuscript on Phase 3 study to be published in Oral Oncology - TheFly
- 6 days ago - Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients - Business Wire
- 23 days ago - CEL-SCI to launch FDA registration-enabling Phase 3 Confirmatory study - TheFly
- 23 days ago - CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer - Business Wire
- 6 weeks ago - CEL-SCI, Saudi Amarox hold strategic agreement signing at BIO 2026 - TheFly
- 6 weeks ago - CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care - Business Wire